Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis

Summary

The purpose of this study is to assess the clinical benefit and tolerability of adalimumab, a fully human monoclonal antibody to tumor necrosis factor α (TNF- α), in patients with ulcerative colitis (UC) naive to treatment with biologics.

Timeline

Start

2012-01

Primary completion

2013-12

Completion

2013-12

Drugs

Indications